Expert Review of Neurotherapeutics最新文献_第5页

Pain relief but at what cost: the need for suicidality screening during chronic pain management. 缓解疼痛，但代价是什么：在慢性疼痛管理期间需要进行自杀筛查。

IF 4.3 2区医学

Expert Review of Neurotherapeutics Pub Date : 2026-08-01 Epub Date: 2026-05-15 DOI: 10.1080/14737175.2026.2673201

Aleksandar Sic, Nebojsa Nick Knezevic

引用次数: 0

Evaluating nipocalimab for the treatment of chronic inflammatory demyelinating polyneuropathy. 尼波卡利单抗治疗慢性炎性脱髓鞘性多神经病变的疗效评价。

IF 4.3 2区医学

Expert Review of Neurotherapeutics Pub Date : 2026-08-01 Epub Date: 2026-05-19 DOI: 10.1080/14737175.2026.2675006

Kazumoto Shibuya, Kazuaki Kito, Tomoki Suichi, Sonoko Misawa, Satoshi Kuwabara

{"title":"Evaluating nipocalimab for the treatment of chronic inflammatory demyelinating polyneuropathy.","authors":"Kazumoto Shibuya, Kazuaki Kito, Tomoki Suichi, Sonoko Misawa, Satoshi Kuwabara","doi":"10.1080/14737175.2026.2675006","DOIUrl":"10.1080/14737175.2026.2675006","url":null,"abstract":"Introduction: Chronic inflammatory demyelinating polyneuropathy (CIDP) is an immune-mediated neuropathy. Established first-line treatments for CIDP included immunoglobulin, corticosteroids, and plasma exchange, whereas the potential efficacy of a neonatal fragment crystallized receptor (FcRn) inhibitor has recently been highlighted. FcRn inhibitors have a selective action on serum IgG reduction, and a phase 2/3 trial with nipocalimab is ongoing, according to the findings of a phase 1 trial.Areas covered: The present article discussed the potential mechanism of action, efficacy, and safety of nipocalimab for CIDP. The safety of nipocalimab was investigated in prior phase 1 trials for healthy participants and phase 2 and 3 trials for myasthenia gravis. Further, efgartigimod has already demonstrated its efficacy in the phase 2 trial and has been approved for CIDP in several countries. Based on these data, the mechanism of action, efficacy, and safety of nipocalimab for CIDP have been assumed.Expert opinion: Nipocalimab represents a novel and potentially effective treatment option for CIDP, and the phase 2/3 trial is ongoing. One thing that clinicians will need to consider is the difference in the route of administration. Regardless, it should be considered positive that new treatment options are emerging for CIDP.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"725-730"},"PeriodicalIF":4.3,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147971864","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An update on the differential diagnosis of migraine in adults: when and how neuroimaging makes the difference. 成人偏头痛鉴别诊断的最新进展：神经成像何时以及如何产生差异。

IF 4.3 2区医学

Expert Review of Neurotherapeutics Pub Date : 2026-08-01 Epub Date: 2026-06-23 DOI: 10.1080/14737175.2026.2693193

Roberta Messina, Alessandro Antoniazzi, Ilaria Cetta, Alessandro Visentini, Federica Genovese, Luca Consuma, Donato Conte, Massimo Filippi

{"title":"An update on the differential diagnosis of migraine in adults: when and how neuroimaging makes the difference.","authors":"Roberta Messina, Alessandro Antoniazzi, Ilaria Cetta, Alessandro Visentini, Federica Genovese, Luca Consuma, Donato Conte, Massimo Filippi","doi":"10.1080/14737175.2026.2693193","DOIUrl":"10.1080/14737175.2026.2693193","url":null,"abstract":"Introduction: Migraine is a highly prevalent and disabling neurological disorder whose diagnosis remains clinical. However, overlap with secondary headache disorders represents a major diagnostic challenge, particularly in patients with atypical features or changes in headache pattern, making neuroimaging crucial in selected cases.Areas covered: This review provides an updated overview of the differential diagnosis of migraine in adults, focusing on the role of clinical assessment, red flags, and neuroimaging in identifying secondary causes. A comprehensive, narrative review of the literature was conducted, integrating current guidelines and recent evidence on imaging indications and modalities. We discuss key conditions that may mimic migraine, including vascular, neoplastic, infectious, cerebrospinal fluid pressure-related, and cervicogenic disorders, highlighting their clinical and radiological features. Attention is given to the concept of pretest probability to guide imaging decisions and to the limitations of red flags in clinical practice.Expert opinion: Neuroimaging should not be routinely performed in patients with typical migraine and normal neurological examination but rather tailored to the individual clinical context. An integrated approach combining clinical judgment, awareness of red flags, and targeted imaging is essential to avoid both underdiagnosis of secondary headaches and overuse of unnecessary investigations.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"777-793"},"PeriodicalIF":4.3,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148294167","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Corticosteroids in withdrawal therapy following medication-overuse headache: a systematic review. 过度用药头痛停药后皮质类固醇治疗：系统综述。

IF 4.3 2区医学

Expert Review of Neurotherapeutics Pub Date : 2026-08-01 Epub Date: 2026-06-22 DOI: 10.1080/14737175.2026.2692440

Evelliny Gomes da Silva, Jonata Ribeiro de Sousa, Manuella Moraes Monteiro Barbosa Barros, Felipe Araújo Andrade de Oliveira, Pedro Augusto Sampaio Rocha-Filho

{"title":"Corticosteroids in withdrawal therapy following medication-overuse headache: a systematic review.","authors":"Evelliny Gomes da Silva, Jonata Ribeiro de Sousa, Manuella Moraes Monteiro Barbosa Barros, Felipe Araújo Andrade de Oliveira, Pedro Augusto Sampaio Rocha-Filho","doi":"10.1080/14737175.2026.2692440","DOIUrl":"10.1080/14737175.2026.2692440","url":null,"abstract":"Introduction: Medication-overuse headache (MOH) affects 1-2% of the population and imposes substantial burden. Corticosteroids are often used as bridge therapy during withdrawal, although their effectiveness remains uncertain. This study aims to evaluate the effectiveness of corticosteroids as a withdrawal strategy in MOH.Methods: A systematic review with meta-analysis was conducted in accordance with PRISMA guidelines. The protocol was registered in PROSPERO (ID: 1161824). Searches were performed in PubMed, MEDLINE, EMBASE, the Cochrane Library, Web of Science, SciELO, and LILACS through June 2025. Randomized, placebo-controlled trials assessing corticosteroids during withdrawal therapy in adults with MOH were included. Random-effects meta-analyses were performed when feasible using RevMan 7.2.0.Results: Of 4,483 records identified, four trials comprising 250 participants met eligibility criteria. Two studies presented high risk of bias, two raised some concerns. Considerable heterogeneity in design, dosing regimens, follow-up duration, and outcome definitions limited comparability and precluded a unified pooled analysis. Across studies, results consistently failed to show benefit. Meta-analytic findings demonstrated no advantage of corticosteroids over placebo regarding early withdrawal headache, withdrawal symptoms or reversal of medication overuse.Conclusion: The available evidence does not support corticosteroids as effective withdrawal therapy for MOH.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"795-804"},"PeriodicalIF":4.3,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148301420","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Multiomics and proteomic insights into Alzheimer's disease biology in Down syndrome. 多组学和蛋白质组学对唐氏综合症阿尔茨海默病生物学的深入研究。

IF 4.3 2区医学

Expert Review of Neurotherapeutics Pub Date : 2026-08-01 Epub Date: 2026-06-29 DOI: 10.1080/14737175.2026.2695187

Mitchell Marta-Ariza, Thomas Wisniewski

{"title":"Multiomics and proteomic insights into Alzheimer's disease biology in Down syndrome.","authors":"Mitchell Marta-Ariza, Thomas Wisniewski","doi":"10.1080/14737175.2026.2695187","DOIUrl":"10.1080/14737175.2026.2695187","url":null,"abstract":"Introduction: Down syndrome (DS) confers a high risk of Alzheimer's disease (AD) and is a genetically determined form of AD. As such, DS provides a uniquely informative biological context in which to investigate AD initiation and progression. Defining the molecular mechanisms that link trisomy 21 to neurodegeneration has broad implications for AD biology and neurotherapeutic development.Areas covered: This review summarizes findings from brain, cerebrospinal fluid, and blood-based proteomic studies, integrated with transcriptomic and multiomics analyses, to characterize molecular pathways underlying AD in DS. The literature was identified through iterative PubMed/MEDLINE searches and manual review of reference lists, considering studies available through June 2026 with no limitation to publication dates.Expert opinion: Brain, lesion-specific, cerebrospinal fluid, and blood-based proteomics, interpreted alongside transcriptomic and complementary omics data, position DSAD as a network-level disorder in which amyloid and tau pathology interact with immune, vascular, metabolic, synaptic, and proteostasis pathways. This integrated proteomic framework helps define shared and subtype-specific mechanisms across DSAD, sporadic AD, and autosomal dominant AD, while supporting biological staging, patient stratification, and therapeutic target discovery.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"745-763"},"PeriodicalIF":4.3,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13478821/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148316412","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Navigating long-acting antipsychotic decision-making in schizophrenia: clinical considerations and best practices. 在精神分裂症中进行长效抗精神病药物决策：临床考虑和最佳实践。

IF 4.3 2区医学

Expert Review of Neurotherapeutics Pub Date : 2026-08-01 Epub Date: 2026-06-04 DOI: 10.1080/14737175.2026.2669300

Justin Faden, Leslie Citrome

引用次数: 0

STS101 nasal powder as a new treatment option for acute migraine with or without aura in adults. STS101鼻粉作为成人伴或无先兆急性偏头痛的新治疗选择

IF 4.3 2区医学

Expert Review of Neurotherapeutics Pub Date : 2026-08-01 Epub Date: 2026-06-03 DOI: 10.1080/14737175.2026.2681528

Bradley Ong, Teshamae S Monteith

{"title":"STS101 nasal powder as a new treatment option for acute migraine with or without aura in adults.","authors":"Bradley Ong, Teshamae S Monteith","doi":"10.1080/14737175.2026.2681528","DOIUrl":"10.1080/14737175.2026.2681528","url":null,"abstract":"Introduction: Although effective acute migraine therapies are available, unmet treatment needs such as nausea, vomiting, or delayed gastric emptying remain. STS101 is a novel dihydroergotamine (DHE) nasal powder designed to treat acute migraine with a simple single.Areas covered: A targeted PubMed and ClinicalTrials.gov search was performed from database inception through October 2025 using the keywords \"STS101,\" \"dihydroergotamine,\" \"migraine,\" and \"intranasal powder.\" Eligible sources included English-language clinical studies, trial registry records, regulatory documents, and relevant conference abstracts addressing STS101 formulation, pharmacokinetics, efficacy, safety, and/or regulatory development. Data from Phase 1 pharmacokinetic trials, the Phase 3 EMERGE and SUMMIT randomized controlled trials, and the ASCEND long-term safety study are discussed.Expert opinion: The pivotal efficacy trials did not meet their 2-hour co-primary endpoints. Later time-point analyses suggested possible clinical benefit, including higher rates of pain freedom and most bothersome symptom freedom from 3 to 48 hours. STS101 may be useful for some patients who prefer a non-oral intranasal rescue option or have had inadequate responses to triptans, gepants or other DHE forms of administration. Its clinical role will likely depend on how clinicians weigh its delivery platform, DHE pharmacology, tolerability, and place relative to other available intranasal options.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"731-744"},"PeriodicalIF":4.3,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148101238","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Choosing the right treatment option for adults with obsessive-compulsive personality disorder. 为成人强迫症患者选择正确的治疗方案。

IF 4.3 2区医学

Expert Review of Neurotherapeutics Pub Date : 2026-07-23 DOI: 10.1080/14737175.2026.2706804

Donatella Marazziti, Riccardo Gurrieri, Leonardo F Fontenelle, Bojana Pejuskovic, Federico Mucci

引用次数: 0

Fremanezumab for migraine in clinical practice: a systematic review and meta-analysis. Fremanezumab治疗偏头痛的临床实践：系统回顾和荟萃分析。

IF 4.3 2区医学

Expert Review of Neurotherapeutics Pub Date : 2026-07-01 Epub Date: 2026-06-14 DOI: 10.1080/14737175.2026.2687476

Jaime Fernández-Bravo-Rodrigo, Carlos Pascual-Morena, Alicia Saz-Lara, Irene Martínez-García, Carla Geovanna Lever-Megina, Silvana Patiño-Cardona, Amparo Flor-García, Iván Cavero-Redondo

{"title":"Fremanezumab for migraine in clinical practice: a systematic review and meta-analysis.","authors":"Jaime Fernández-Bravo-Rodrigo, Carlos Pascual-Morena, Alicia Saz-Lara, Irene Martínez-García, Carla Geovanna Lever-Megina, Silvana Patiño-Cardona, Amparo Flor-García, Iván Cavero-Redondo","doi":"10.1080/14737175.2026.2687476","DOIUrl":"10.1080/14737175.2026.2687476","url":null,"abstract":"Introduction: Although the efficacy of fremanezumab in treating migraine has been proven in randomized controlled trials, its effectiveness is not well understood. Consequently, this study purpose was to synthesize and estimate its real-world effectiveness and safety in patients with migraine.Methods: A systematic search of PubMed, Scopus and Web of Science was conducted from inception to November2025. Real-world studies evaluating fremanezumab effectiveness, measured by monthly migraine days (MMDs), monthly headache days (MHDs), Headache Impact Test (HIT-6) and related outcomes, including safety, were included. Random-effects meta-analyses were performed.Results: One month after treatment initiation, fremanezumab reduced MMD by -5.82 days (95% CI: -6.67, -4.97), MHD by -7.30 days (95% CI: -9.72, -4.87) and HIT-6 scores by -6.84 points (95% CI: -10.30, -3.39). Approximately 50% of patients achieved a ≥ 50% reduction in MMD or MHD within 3 months, with response rates increasing progressively up to 12 months. Adverse event rates were 0.05 (95% CI: 0.02, 0.09) in 6 months and 0.07 (95% CI: 0.03, 0.12) in 12 months, with constipation being the most frequently reported event.Conclusion: Fremanezumab is associated with clinically significant reductions in migraine frequency, disability and acute medication used in real-world settings, with a favorable safety profile.Prospero: CRD42021266322.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"687-699"},"PeriodicalIF":4.3,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148249902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Profiling galcanezumab in episodic migraine, cluster headache, and medication overuse headache. galcanezumab在发作性偏头痛、丛集性头痛和药物滥用性头痛中的临床应用。

IF 4.3 2区医学

Expert Review of Neurotherapeutics Pub Date : 2026-07-01 Epub Date: 2026-05-25 DOI: 10.1080/14737175.2026.2675009

Abimael González-Hernández, José D Ferrusca, Carlos M Villalón

{"title":"Profiling galcanezumab in episodic migraine, cluster headache, and medication overuse headache.","authors":"Abimael González-Hernández, José D Ferrusca, Carlos M Villalón","doi":"10.1080/14737175.2026.2675009","DOIUrl":"10.1080/14737175.2026.2675009","url":null,"abstract":"Introduction: The introduction of monoclonal antibodies (mAbs) targeting the calcitonin gene-related peptide (CGRP) pathway has revolutionized migraine treatment. In this regard, galcanezumab, a humanized immunoglobulin G4 (IgG4) that binds the CGRP molecule, has rapid onset of action, monthly dosing, and favorable pharmacokinetics.Areas covered: This review, which draws upon electronic databases such as PubMed, Web of Science, FDA, and EMA, provides a comprehensive summary of galcanezumab for migraine prophylaxis. It covers the drug's mechanism of action, its clinical efficacy in episodic migraine, and its potential benefits in episodic cluster headache and medication-overuse headache. It also provides an overall safety profile based on clinical trials and real-world studies.Expert opinion: Galcanezumab is a cornerstone preventive therapy with consistent efficacy, favorable tolerability, and convenient dosing. Key unmet needs include identifying biomarkers to predict responders, addressing access and cost barriers, optimizing evaluation windows for late-responders, and expanding the evidence base for special populations (pediatrics, pregnancy, and vascular comorbidities). Future studies should refine patient selection and explore complementary targets for non-responders.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"619-629"},"PeriodicalIF":4.3,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148014263","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0